Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
16 mai 2023 18h53 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
15 mai 2023 07h00 HE
|
Akero Therapeutics
-- Results from Cohort D, an expansion cohort of type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 agonist, to be reported during the second quarter...
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
29 mars 2023 16h01 HE
|
Akero Therapeutics
The planned Phase 3 program consists of three trials, SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes to evaluate the safety and efficacy of efruxifermin (EFX) in patients with...
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
17 mars 2023 07h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
10 janv. 2023 08h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 08h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
21 déc. 2022 16h01 HE
|
Akero Therapeutics
Results of the main study in patients with compensated cirrhosis due to NASH (F4) expected in fourth quarter of 2023 Results of the cohort D expansion to evaluate EFX in combination with GLP-1...
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
08 déc. 2022 07h00 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
10 nov. 2022 16h05 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
07 nov. 2022 07h30 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...